All News from Accelerate Diagnostics

All News

Accelerate Diagnostics Schedules First-Quarter 2016 Results Announcement and Webcast

Apr 25, 2016 — Accelerate Diagnostics, Inc. announced today it will report first-quarter 2016 financial results after market close on Thursday, May 12, 2016.

Continue reading ›

Accelerate Diagnostics to Present Data at European Congress

Apr 10, 2016 — Accelerate Diagnostics, Inc. announced today it will present data related to the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for positive blood cultures while attending the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, Netherlands.

Continue reading ›

District Court Dismisses Lawsuit Against Accelerate Diagnostics

Jan 29, 2016 — Accelerate Diagnostics, Inc. (Nasdaq:AXDX) ("Accelerate Diagnostics") announced today that the United States District Court for the District of Arizona granted Accelerate Diagnostics' Motion to Dismiss the class action lawsuit filed against it in March of 2015.

Continue reading ›

Accelerate Diagnostics to Present at the J.P. Morgan 34th Annual Healthcare Conference on January 12th

Jan 05, 2016 — Accelerate Diagnostics, Inc. (Nasdaq:AXDX) announced today that Lawrence Mehren, President and Chief Executive Officer, is scheduled to present at the J.P. Morgan 34th Annual Healthcare Conference in San Francisco, CA on Tuesday, January 12th at 7:30 AM PST / 10:30 AM EST. A live audio webcast of the presentation will be accessible from the investor […]

Continue reading ›

Accelerate Diagnostics Completes $109 Million Offering, Underwriters Exercise in Full Their Option to Purchase Additional Shares

Dec 15, 2015 — Accelerate Diagnostics, Inc. (Nasdaq:AXDX) announced that it completed a public offering of 6,426,471 shares of common stock today at a previously disclosed price per share of $17.00 which includes 838,235 shares issued and sold to the underwriters who exercised in full their option to purchase additional shares of common stock. The gross proceeds to Accelerate […]

Continue reading ›

Accelerate Diagnostics Announces Pricing of Public Offering of Common Stock

Dec 09, 2015 — Accelerate Diagnostics, Inc. (Nasdaq:AXDX) today announced the pricing of an underwritten public offering of 5,588,236 shares of its common stock at a price to the public of $17.00 per share. All of the shares are being sold by Accelerate Diagnostics. The gross proceeds toAccelerate Diagnostics from the offering, before deducting the underwriting discounts and commissions […]

Continue reading ›

Accelerate Diagnostics Announces Proposed Public Offering of Common Stock

Dec 08, 2015 — Accelerate Diagnostics, Inc. (Nasdaq:AXDX) today announced that it has commenced an underwritten public offering of $80 million of shares of its common stock. All of the shares are being offered by Accelerate Diagnostics. In addition, Accelerate Diagnostics expects to grant the underwriters of the offering a 30-day option to purchase up to an additional $12 […]

Continue reading ›

Accelerate Diagnostics Reports Positive Results From Pilot Study of Its Investigational ID/AST System and Blood Culture Assay Kit and Initiation of Trial to Support FDA Clearance

Dec 02, 2015 — Accelerate Diagnostics, Inc. announced positive findings from a multicenter pilot study to evaluate external performance of its ID/AST System and Blood Culture Assay Kit. Based on the results of the study, the company also announced the initiation of its clinical trial for submission to the U.S. Food and Drug Administration. The Accelerate ID/AST System is […]

Continue reading ›

Accelerate Diagnostics to Present at the 27th Annual Piper Jaffray Healthcare Conference on December 2, 2015

Dec 01, 2015 — Accelerate Diagnostics, Inc. (Nasdaq:AXDX) announced today that Lawrence Mehren, Chief Executive Officer, is scheduled to present a corporate update at the Piper Jaffray Healthcare Conference in New York City, NY on Wednesday, December 2nd at 12:30 PM ET. About Accelerate Diagnostics, Inc. Accelerate Diagnostics, Inc. (Nasdaq:AXDX), is an in vitro diagnostics company dedicated to providing […]

Continue reading ›

Accelerate Diagnostics to Present at the 35th Annual Canaccord Genuity Growth Conference on August 13, 2015

Aug 05, 2015 — Accelerate Diagnostics, Inc. (NASDAQ:AXDX), an in vitro diagnostics company dedicated to providing solutions for the global challenge of drug resistant organisms and hospital acquired infections, announced today that Lawrence Mehren, Chief Executive Officer, is scheduled to present a corporate update at the Canaccord Genuity Growth Conference in Boston, MA on Thursday, August 13th at 8:00AM […]

Continue reading ›